Interpace Diagnostics (IDXG) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Interpace Diagnostics Group Reports Second Quarter 2018 Financial Results, Business Progress and Recent Accomplishments
August 9, 2018 4:47 PM EDTRevenue Grew 43% Over the Prior Years Quarter and 14% Over the Prior Period
Record Quarterly Revenue of $5.5 Million
Cash & Cash Equivalents of $10.1 Million with No Long-Term Debt
Now Covered by 27 Regional Blue Cross/Blue Shield Plan for ThyGenX® and ThyraMIR®
Company Successfully Launched New Mutational Panel for Thyroid: ThyGeNEXT
Guidance of Revenues for the Year of Over $20 Million Reaffirmed
Conference Call Thursday August 9, 2018 at 4:30 pm ET
Parsippany, NJ, Aug. 09, 2018 (GLOBE NEWSWIRE) --... More
